Isunakinra

DB12373InvestigationalProtein Based Therapies

Isunakinra has been investigated for the treatment of Dry Eye and Allergic Conjunctivitis (AC).

Mechanism: Pharmacologically active on Interleukin-1 receptor type 1
Curator reviewed
Code names: EBI-005

Resolves to

Compound

Targets

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Isunakinra, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.